Drug Type Small molecule drug |
Synonyms Iron Polysaccharide Complex, Niferex, PIC + [3] |
Target- |
Mechanism Fe modulators |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Drug Highest PhaseApproved |
First Approval Date US (10 Jan 2017), |
Regulation- |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Iron deficiency | US | 10 Jan 2017 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Menopause, Premature | Phase 3 | CA | 16 Dec 2014 | |
Anemia, Iron-Deficiency | Phase 3 | US | 03 Sep 2014 | |
Dyspnea | Phase 3 | US | 03 Sep 2014 | |
Fatigue | Phase 3 | US | 03 Sep 2014 | |
stomach adenocarcinoma | Phase 1 | US | 30 Mar 2022 | |
Coronary Stenosis | Phase 1 | CN | 13 Oct 2021 | |
Plaque, Atherosclerotic | Phase 1 | CN | 13 Oct 2021 | |
Chronic Kidney Diseases | Phase 1 | CN | 17 Sep 2021 | |
Renal Artery Obstruction | Phase 1 | CN | 17 Sep 2021 | |
Pain | Phase 1 | US | 30 Sep 2014 |
Not Applicable | - | Iron Polysaccharide | rnmebzvpqw(gydgnuczza) = only one patient complained of gastrointestinal side effect bgsaptxhau (sbhtnyvbqg ) | Positive | 13 Jun 2019 | ||
Placebo | |||||||
Phase 4 | 22 | placebo+Niferex (Placebo & Niferex) | nyxrbkkfvz(vgijqbamxt) = gpuqdybxdx wxuwwqvfzs (chmzdsydms, yxsiuvagsk - clmxdfmina) View more | - | 11 Nov 2013 | ||
epoetin alpha+Niferex (Epoetin Alpha & Niferex) | nyxrbkkfvz(vgijqbamxt) = dqbsxrxcst wxuwwqvfzs (chmzdsydms, dsgymadgme - kfchdxorot) View more |